When it came time to evaluate the safety of COVID-19 vaccines, the FDA tapped into Optum Scientific Consulting's 25 year history of conducting drug and vaccine safety. Optum Chief Scientific Officer John Seeger discusses the companies role in evaluating vaccines for kids ages 5 to 11 and the broader impact data has on drug and vaccine safety.